Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: Clin Cancer Res. 2017 Sep 26;23(24):7474–7482. doi: 10.1158/1078-0432.CCR-17-2005

Figure 1.

Figure 1

Ipilimumab enhances the expression of activation markers on peripheral CD4 and CD8 T cells. A, Study design of treatment and sample collection. B, Immune snapshot of HLA-DR and ICOS expression on CD4 T cells in a representative patient. C and D, Changes in the expression of ICOS, (E and F) HLA-DR, (G and H) CTLA-4, and (I and J) PD-1 on CD4 (C, E, G, and I) and CD8 T cells (D, F, H, and J) were examined by flow cytometry analysis. Frequency of gated CD4 or CD8 T cells are shown for 24 patients at pre-treatment (V1), post-chemotherapy only (V2), and post-chemotherapy and ipilimumab (V3) timepoints. Statistical significance is represented by **** p ≤ 0.0001. Mean and SD are shown.